Creative Medical Technology vs Inmune Bio
CELZ and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELZ and INMB compare
Inmune Bio is the larger company, worth 7.4 times as much as Creative Medical Technology ($30.5M against $4.2M).
Creative Medical Technology scores higher on the StockData Score (7 against 6 for Inmune Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELZ | INMB |
|---|---|---|
| Size and price | ||
| Market cap | $4.2M | $30.5M |
| Share price | $0.630 | $1.10 |
| Change, 1 year | −80.8% | −30.4% |
| Change, 5 years | −98.2% | −91.8% |
| Beta (5Y) | 1.56 | 1.33 |
| Employees | – | 6 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1384× | – |
| P/B | 0.6× (better) | 1.7× |
| Growth | ||
| Revenue growth (TTM) | −50.0% | – |
| Revenue growth, 5Y average | −48.4% | 35.4% (better) |
| Profitability | ||
| Gross margin | 66.9% | – |
| Operating margin | −256435% | – |
| Net margin | −249160% | – |
| Return on equity | −119% | −76.7% (better) |
| Return on invested capital | −3737% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 23.66 (better) | 6.41 |
| Altman Z-score | −8.55 (better) | −10.86 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −190% | – |
| Shareholder yield | −190% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 5.7% | 15.7% |
| Held by insiders | 15.9% | 16.7% |
| Short interest, % of float | 1.2% | 11.5% |
Go deeper
- CELZ stock overview
- CELZ income statement
- CELZ valuation and score
- INMB stock overview
- INMB income statement
- INMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.